Acucela Issues Notice of Resolutions of the Annual Meeting of Shareholders

SEATTLE--(BUSINESS WIRE)--Acucela Inc. (Tokyo: 4589) (the “Company”), a clinical-stage ophthalmology company that specializes in identifying and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases, hereby gives notice that the following matters were resolved at the Annual Meeting of Shareholders of the Company held on October 18, 2016 Pacific Time in Seattle, Washington. Proposal 1: Adoption of the Merger Agreement The merger agreement (the “